Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/38759
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPantelis C.en
dc.contributor.authorSundram S.en
dc.contributor.authorWeickert C.S.en
dc.contributor.authorEverall I.en
dc.contributor.authorBousman C.en
dc.contributor.authorMostaid M.S.en
dc.contributor.authorLee T.T.en
dc.contributor.authorChana G.en
dc.date.accessioned2021-05-14T13:14:04Zen
dc.date.available2021-05-14T13:14:04Zen
dc.date.copyright2017en
dc.date.created20171121en
dc.date.issued2017-11-21en
dc.identifier.citationFrontiers in Psychiatry. 8 (NOV) (no pagination), 2017. Article Number: 225. Date of Publication: 06 Nov 2017.en
dc.identifier.issn1664-0640 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/38759en
dc.description.abstractInvestigation of peripheral gene expression patterns of transcripts within the NRG-ErbB signaling pathway, other than neuregulin-1 (NRG1), among patients with schizophrenia and more specifically treatment-resistant schizophrenia (TRS) is limited. The present study built on our previous work demonstrating elevated levels of NRG1 EGFalpha, EGFbeta, and type I(Ig2) containing transcripts in TRS by investigating 11 NRG-ErbB signaling pathway mRNA transcripts (NRG2, ErbB1, ErbB2, ErbB3, ErbB4, PIK3CD, PIK3R3, AKT1, mTOR, P70S6K, eIF4EBP1) in whole blood of TRS patients (N = 71) and healthy controls (N = 57). We also examined the effect of clozapine exposure on transcript levels using cultured peripheral blood mononuclear cells (PBMCs) from 15 healthy individuals. Five transcripts (ErbB3, PIK3CD, AKT1, P70S6K, eIF4EBP1) were significantly elevated in TRS patients compared to healthy controls but only expression of P70S6K (Pcorrected = 0.018), a protein kinase linked to protein synthesis, cell growth, and cell proliferation, survived correction for multiple testing using the Benjamini-Hochberg method. Investigation of clinical factors revealed that ErbB2, PIK3CD, PIK3R3, AKT1, mTOR, and P70S6K expression were negatively correlated with duration of illness. However, no transcript was associated with chlorpromazine equivalent dose or clozapine plasma levels, the latter supported by our in vitro PBMC clozapine exposure experiment. Taken together with previously published NRG1 results, our findings suggest an overall upregulation of transcripts within the NRG-ErbB signaling pathway among individuals with schizophrenia some of which attenuate over duration of illness. Follow-up studies are needed to determine if the observed peripheral upregulation of transcripts within the NRG-ErbB signaling pathway are specific to TRS or are a general blood-based marker of schizophrenia.Copyright © 2017 Mostaid, Lee, Chana, Sundram,Shannon Weickert, Pantelis, Everall and Bousman.en
dc.languageenen
dc.languageEnglishen
dc.publisherFrontiers Media S.A. (E-mail: info@frontiersin.org)en
dc.relation.ispartofFrontiers in Psychiatryen
dc.titlePeripheral transcription of NRG-ErbB pathway genes are upregulated in treatment-resistant schizophrenia.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.3389/fpsyt.2017.00225en
dc.publisher.placeSwitzerlanden
dc.identifier.source619147754en
dc.identifier.institution(Mostaid, Pantelis, Everall, Bousman) Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia (Mostaid, Pantelis, Everall, Bousman) The Cooperative Research Centre (CRC) for Mental Health, Melbourne, VIC, Australia (Lee, Chana, Pantelis, Everall) Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia (Chana, Sundram, Pantelis, Everall) Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia (Chana) Department of Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia (Sundram, Pantelis, Everall) NorthWestern Mental Health, Melbourne, VIC, Australia (Sundram) Department of Psychiatry, School of Clinical Sciences, Monash University and Monash Health, Clayton, VIC, Australia (Weickert) Schizophrenia Research Institute, Sydney, NSW, Australia (Weickert) Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, Australia (Weickert) Faculty of Medicine, School of Psychiatry, University of New South Wales, Sydney, NSW, Australia (Everall) Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom (Bousman) Department of Medical Genetics, University of Calgary, Calgary, AB, Canada (Bousman) Department of Psychiatry, University of Calgary, Calgary, AB, Canada (Bousman) Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canadaen
dc.description.addressC. Bousman, Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Parkville, VIC, Australia. E-mail: chad.bousman@ucalgary.caen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2017 Elsevier B.V., All rights reserved.en
dc.subect.keywordsGene expression NRG-ErbB pathway Schizophrenia Symptom severity Treatment-resistant schizophreniaen
dc.identifier.authoremailBousman C.; chad.bousman@ucalgary.caen
dc.description.grantOrganization: (BBRF) *Brain and Behavior Research Foundation* Organization No: 100000874 Country: United States Organization: (MRC) *Medical Research Council* Organization No: 501100000265 Country: Denmark No: 1105825 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: 1127700 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: 386500 Organization: (MRC) *Medical Research Council* Organization No: 501100000265 Country: Denmark No: 628386 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australiaen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptMental Health-
Appears in Collections:Articles
Show simple item record

Page view(s)

12
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.